Panacea Biotec Tuesday said its board has approved raising up to Rs 864 crore for one-time settlement with its lenders and other purposes.
The company will raise the funds through issue of non convertible debentures on a private placement basis, Panacea Biotec said in a regulatory filing.
The capital once raised would be utilised by the company for one-time settlement with the consortium of lenders and for the settlement of stretched payables, employees' dues and for working capital requirements, among others, it added.
The board also approved demerger of the company's real estate business with few modifications to the scheme of arrangement approved by the board in September 2017.
The company has also convened an extraordinary general general meeting (EGM) on March 25, during which the shareholders will consider company's plans to raise up to Rs 128 crore via issue of warrants on a preferential basis.
The shareholders would also consider transfer of the pharmaceutical formulations business of the company to a wholly-owned subsidiary as a going concern.
Panacea shares Tuesday ended marginally up at Rs 193.60 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
